bluebird bio Announces Topics for Gene Therapy Day, October Investor Presentation

CAMBRIDGE, Mass.–(BUSINESS WIRE)– bluebird bio, Inc. (Nasdaq:
BLUE), a clinical-stage company committed to developing potentially
transformative gene therapies for severe genetic diseases and T
cell-based immunotherapies for cancer, today announced the agenda and
speakers for its Gene Therapy Day, starting at 9:00 am ET on October 13,
2016 at Le Parker Meridien New York City.

• Jeff Walsh, chief financial and strategy officer, will outline the
  company’s long-term R&D strategy
• Philip Gregory, D.Phil., chief scientific officer, will present
  transduction efficiency in vitro comparison data from
  manufacturing process 1 vs. process 2 in retained patient samples as
  well as highlights of the company’s progress in scalable manufacturing
• Mohammed Asmal, M.D., senior medical director, will discuss the
  company’s current and future efforts to optimize patient outcomes in
  sickle cell disease
• Anne-Virginie Eggimann, vice president, regulatory science, will
  provide an update on regulatory progress and plans for LentiGlobin^TM
  product candidate in transfusion-dependent β-thalassemia

Nick Leschly, chief bluebird and David Davidson, M.D., chief medical
officer, will also participate in the event.

bluebird will also present at the Jefferies Gene Therapy and Editing
Summit on October, 11, 2016 at 9:40 am ET (company presentation) and
10:00 am ET (Panel Discussion on Gene Editing). This conference will be
held at the Jefferies Conference Center in New York City.

To access the live webcasts, please visit the “Events & Presentations”
page within the Investors and Media section of the bluebird bio website
at http://investor.bluebirdbio.com.
Replays of the webcasts will be available on the bluebird bio website
for 90 days following the event.

About bluebird bio, Inc.

With its lentiviral-based gene therapies, T cell immunotherapy expertise
and gene editing capabilities, bluebird bio has built an integrated
product platform with broad potential application to severe genetic
diseases and cancer. bluebird bio’s gene therapy clinical programs
include its Lenti-D™ product candidate, currently in a
Phase 2/3 study, called the Starbeam Study, for the treatment of
cerebral adrenoleukodystrophy, and its LentiGlobin™ BB305 product
candidate, currently in four clinical studies for the treatment of
transfusion-dependent β-thalassemia, and severe sickle cell disease.
bluebird bio’s oncology pipeline is built upon the company’s leadership
in lentiviral gene delivery and T cell engineering, with a focus on
developing novel T cell-based immunotherapies, including chimeric
antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird
bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program
partnered with Celgene. bb2121 is currently being studied in a Phase 1
trial for the treatment of relapsed/refractory multiple myeloma.
bluebird bio also has discovery research programs utilizing
megaTALs/homing endonuclease gene editing technologies with the
potential for use across the company’s pipeline.

bluebird bio has operations in Cambridge, Massachusetts; Seattle,
Washington; and Paris, France.

Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the Company’s product candidates and research programs. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, risks that the preliminary results from our clinical trials will not
continue or be repeated in our ongoing clinical trials, the risk of
cessation or delay of any of the ongoing or planned clinical studies
and/or our development of our product candidates, the risk of a delay in
the enrollment of patients in our clinical studies, the risk that our
collaboration with Celgene will not continue or will not be successful,
and the risk that any one or more of our product candidates will not be
successfully developed, approved or commercialized. For a discussion of
other risks and uncertainties, and other important factors, any of which
could cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors” in
our most recent quarterly report on Form 10-Q, as well as discussions of
potential risks, uncertainties, and other important factors in our
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
bluebird bio undertakes no duty to update this information unless
required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161006005306/en/